Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

Abstract

Most patients with non-small cell lung cancer (NSCLC) present with advanced disease requiring systemic chemotherapy. Treatment with the antiangiogenic agent bevacizumab in combination with standard platinum-based doublet chemotherapy has been shown to improve outcomes in patients with advanced NSCLC. Several multitargeted antiangiogenic tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, cediranib, vandetanib, BIBF 1120, pazopanib, and axitinib) are also being evaluated in combination with standard chemotherapy. Here we review current clinical data with combination therapy involving antiangiogenic agents and cytotoxic chemotherapy in patients with advanced NSCLC.

5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma

“…Several studies have addressed the combination therapy of sorafenib/sunitinib and chemotherapeutic reagents, such as platinum, taxane, and gemcitabine (9)(10)(11)(12)(13)(14), whereas only a small number of studies have evaluated the combination with fluorinated pyrimidine (11,22). The present findings are consistent with the result reported by Takeuchi et al (22), who examined the combination effect of S-1 (an oral fluorinated pyrimidine) and sorafenib for RCC treatment in vitro and in tumor-bearing murine models.…”

“…In addition to promising preclinical and clinical data culminating in the approval of sorafenib and sunitinib, their mechanism of action, good safety and tolerability indicate that they may be a useful treatment option in combination with conventional chemotherapy for advanced solid cancers. Several studies have evaluated the effect of sorafenib or sunitinib in combination with a variety of anticancer agents in various types of tumor (9)(10)(11)(12)(13)(14).…”

99mTc-3P-RGD2 Micro-Single-Photon Emission Computed Tomography/Computed Tomography Provides a Rational Basis for Integrin αvβ3-Targeted Therapy

“…Nevertheless, the affinity to A549 and NCI-H446 differed both in vitro and in vivo, which correlated with a v b 3 expression level RGD 2 micro-SPECT/CT provided quantitative data of integrin a v b 3 in tumors, which forms a basis for its use in a v b 3 -targeted therapy. [13][14][15][16][17] Further studies are warranted.…”

“…In recent years, the use of anti-angiogenesis therapy, anti-integrin a v b 3 therapy, RGD-related chemotherapy, and gene therapy has rapidly developed. [13][14][15][16][17][18] However, the expression level of integrin a v b 3 varies in different tumors, and the limited knowledge of a v b 3 expression in patient tumors has restricted the broad application of anti-a v b 3 therapy in clinical settings. Noninvasive imaging of a v b 3 -positive tumors and quantification of a v b 3 expression levels are important not only for diagnosis, but also for choosing appropriate treatment strategies and monitoring the response to therapy.…”

Study of the combined treatment of lung cancer using gene-loaded immunomagnetic albumin nanospheres in vitro and in vivo

“…According to its pathological and clinical characteristics, lung cancer can be classified into two major categories: small cell-lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). 1 The primary treatment strategy for lung cancer is surgery. Because the early symptoms of lung cancer are difficult to detect, from 70% to 80% of lung cancer cases were identified at an advanced or metastatic stage.…”